Literature DB >> 6437308

Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study.

C E Stevens, R D Aach, F B Hollinger, J W Mosley, W Szmuness, R Kahn, J Werch, V Edwards.   

Abstract

Patients who received transfusions and nontransfused control patients were followed to assess the incidence and cause of post-transfusion hepatitis and to identify donor factors that might relate to risk of hepatitis. We evaluated as risk factors in donors the presence of antibody to hepatitis B virus compared with elevated alanine aminotransferase (ALT) level. Units of blood that were positive for antibody to hepatitis B core antigen (anti-HBc) were associated with a twofold to threefold greater risk of non-A, non-B hepatitis in the recipients than were units without anti-HBc. In the absence of specific serologic tests for non-A, non-B agents, screening of donors for anti-HBc might be considered. Our data suggest that the incidence of non-A, non-B hepatitis might have been reduced by about one third by such screening. However, elevated ALT levels in donors had a similar association with non-A, non-B hepatitis in recipients but would have resulted in fewer units of blood being discarded than would screening for anti-HBc.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437308     DOI: 10.7326/0003-4819-101-6-733

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  39 in total

1.  Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis. The EATHIS Eco Research Group. European Acute Transfusion Hepatitis Interferon Study.

Authors:  C Colin; P Vergnon; A M Jullien; S Excoffier; Y Matillon; C Trepo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

2.  Improvement in the specificity of assays for detection of antibody to hepatitis B core antigen.

Authors:  J A Weare; E F Robertson; G Madsen; R Hu; R H Decker
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 3.  Leucoreduction of blood components: an effective way to increase blood safety?

Authors:  Maria Bianchi; Stefania Vaglio; Simonetta Pupella; Giuseppe Marano; Giuseppina Facco; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

Review 4.  Blood transfusion and hepatitis: still a threat?

Authors:  H W Reesink; C L van der Poel
Journal:  Blut       Date:  1989-01

5.  Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay.

Authors:  A M Spronk; L Schmidt; C Krenc; L Pavlis-Jenkins; J Brady; S Taskar; L Angus-Finn; L Mimms
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

6.  Characterization of a reduction-sensitive factor from human plasma responsible for apparent false activity in competitive assays for antibody to hepatitis B core antigen.

Authors:  E F Robertson; J A Weare; R Randell; P V Holland; G Madsen; R H Decker
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

7.  Is screening of blood donors for anti-HBc useful?

Authors:  G Caspari; H J Beyer; H Schmitt; W Gerlich; A Uy; R Thomssen
Journal:  Blut       Date:  1990-06

8.  Searching for unknown transfusion-transmitted hepatitis viruses: a binational cohort study of 1.5 million transfused patients.

Authors:  G Edgren; H Hjalgrim; K Rostgaard; V Dahl; K Titlestad; C Erikstrup; A Wikman; R Norda; A Majeed
Journal:  J Intern Med       Date:  2018-04-25       Impact factor: 8.989

9.  Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen.

Authors:  D Lavanchy; C Mayerat; B Morel; P Schneider; C Zufferey; J J Gonvers; A Pécoud; P C Frei
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

10.  Enzyme immunoassay for anti-hepatitis B core (HBc) immunoglobulin G1 and significance of low-level results in competitive assays for anti-HBc.

Authors:  M Sällberg; L O Magnius
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.